Marker Therapeutics Inc (MRKR)

[Gatta-git-it]

Monday is the Q3 reporting date.

It would be welcomed that even though a loss will be reported, that the cash runway is sufficient onto late 2022. Moreover, what would be well received after 9 weeks of silence, would be a detailed presentation of each item in the pipeline.. meaning the progress being made, a sense of the research and clinical future results.

If done, perhaps the long time absent posters might return and offer up thoughts.

However, if the company means of reporting is again lackluster, all of us realize that the share price will again fall.
These many months below $5 has been painful and weary. Glta.